A Ru(II) polypyridyl complex bearing aldehyde functions as a versatile synthetic precursor for long-wavelength absorbing photodynamic therapy photosensitizers

Rationally designed ruthenium complexes for 1- and 2-photon photodynamic therapy

“…In agreement with theoretical findings, the compounds generally show a red-shift of the first 1P absorption ( Fig. 2a) band maximum of about 50-70 nm for the symmetric Ru(II) complexes, in comparison to Ru(2,2′-bipyridine) 3 45 as well as an absorption tail toward the near-infrared region. Strikingly and in agreement with theoretical data, the reported compounds have an exceptionally strong 2P absorption ( Fig.…”

Metal dipyrrin complexes as potential photosensitizers for photodynamic therapy

“…Therefore, much efforts are devoted towards the development of transition metal complexes as PDT PSs. 40 The majority of complexes studied are based on Ru(II), [41][42][43][44][45][46][47][48][49][50][51] Os(II), [52][53][54] Ir(III), [55][56][57][58][59][60][61] Rh(III) [62][63][64] and Re(I). [65][66][67][68][69] As these metals are expensive, it would be of high interest to develop PSs based on cheap, abundant metals.…”

Increased Lipophilicity of Halogenated Ruthenium(II) Polypyridyl Complexes Leads to Decreased Phototoxicity in vitro when Used as Photosensitizers for Photodynamic Therapy

“…In acetonitrile, 1-5 showed high φ values ranging from 58 to 88 % upon irradiation at 420 nm, which are comparable to structurally similar ruthenium polypyridyl complexes reported previously. [10,12,14,15,66] However, we noted that φ values are much lower (2-6 %) when measured in PBS. This observation is consistent with our previous studies on polypyridyl complexes and attributed to the interaction of the dppz ligands with water molecules, which does not allow energy transfer to molecular oxygen.…”

“…[7] More recently, Ru II polypyridyl complexes have sparked great interest due to their exceptional properties, including generally good water solubility, high 1 O 2 production rates and high photochemical stability as well as original mode of actions related to their unique intracellular distribution (i. e., mitochondria, nucleus, lysosome, etc). [8][9][10][11][12][13][14][15][16][17][18] As a proof of the promising nature of these third-generation PSs, TLD-1433 ( Figure 2) has recently entered a phase II clinical trial for the treatment of non-muscle invasive bladder cancer. [7,19] Over the years, in order to increase chemotherapeutics efficacy, reduce side effects and overcome resistance mechanisms, the development of organelle-targeted drugs appeared highly beneficial.…”